Recombinant humanized anti-TIGIT monoclonal antibody(Lepu biopharma)

重组人源化抗TIGIT单克隆抗体（乐普生物）

Report date: 2022/09/23 14:19:45

Base Information

Drug NameRecombinant humanized anti-TIGIT monoclonal antibody(Lepu biopharma)
Drug Alias NameLP-010
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionT lymphocytes stimulantsNatural killer cells stimulantsT cell immunoglobulin and ITIM domains inhibitors
TargetsT cell immunoglobulin and ITIM domains
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesLepu Biopharma Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesLepu Biopharma Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A